To render mouse or rat monoclonal antibodies suitable for human therapy, there is a requirement for antibody engineering. The antibody (mAb) will be humanized and optimized by Millegen using its patented MutaGen technology. MilleMAb platform, directed towards the development of humanized therapeutic antibody candidates with superior and significantly enhanced properties.
